IMCAS Academy

Inscribirse

Conectarse

Presentación
Programa
Oradores
Listado de sponsors
Acreditación

VOLVER

IMCAS World Congress 2019
Programa

FOCO EN S085

Melasma: change the color of your skin (in collaboration with SMD)

Partner of the session

SMD

Société Marocaine de Dermatologie

Marruecos

Programa

Sala: Amphi Havane (level 3)
Fecha: jueves 31 enero 2019 de 14:00 a 15:00
Formato: SESIÓN ENFOCADA > presentación que cubre una temática principal del congreso

Moderador

Dr Mukta SACHDEV

Dermatólogo

India

Las presentaciones

Horas	Oradores	Título de la presentación	Resumen	Número
14:17	Dr Behrooz KASRAEE	Skin depigmenting agent: what's new (Cysteamine and others)?	Ver	78633
14:29	Prof Philippe HUMBERT	Benefits of oral supplementation for melasma		78635
14:41	Prof Desmond J TOBIN	Modulation of skin pigmentation with topicals	Ver	71531

Ver la sala anterior (Amphi Bordeaux (level 3))

Ver la siguiente sesión

Sesiones recomendadas

Pigmentación

Melasma

Vitiligo

Cosmecéuticos

Terapias tópicas

Dr Behrooz KASRAEE

Dermatólogo

Francia

Otro(s) autor(es) :

Skin depigmenting agent: what's new (Cysteamine and others)?

Objectives: Melasma and post-inflammatory hyperpigmentation (PIH) are frequent skin hyperpigmentary disorders which can present therapeutic challenges for the clinician. The therapeutic armamentarium against melasma and PIH is being significantly changed during the past years mainly due to the safety issues regarding the gold standard treatment, hydroquinone followed by its ban in several countries and on the other hand the emerge of depigmenting molecules with a better safety profile into the market.

Introduction: In this presentation, new therapeutic options for melasma and PIH as well as their safety and efficacy profiles will be presented. Some oral and parenteral skin depigmenting agents (e.g. tranexamic acid) as well as biogenic depigmenting compounds (e.g. L-cysteamine) will be discussed.

Results: Cysteamine hydrochloride is known for its potent depigmenting effect since 1960's when Chavin tested it through injecting cysteamine into the black goldfish skin (1). A few years later, different in vivo studies showed the higher depigmenting efficacy of this molecule compared to hydroquinone (2). Superiority to hydroquinone was recently confirmed in vitro (3). However, cysteamine has never been utilizable in human mainly due to the very offensive odor it produced in topical products. Results for a comparative study with Kligman formula will be presented.

Conclusion: Cysteamine is biologically produced in mammalian cells and serves as an intracellular anti-oxidant. This molecule is FDA approved as eye-drops and as an oral medication and has a long history of safety for human use. The anti-mutagenic and anti-carcinogenic effects of cysteamine are previously shown in numerous studies. With its high efficacy and safety profiles, topical cysteamine has a higher benefit/risk ratio compared to hydroquinone and might serve as a new safe and effective skin depigmenting agent for the treatment of hyperpigmentary disorders such as melasma.

Declaraciones

¿Ha recibido algún tipo de financiamiento para realizar su investigación sobre esta temática?
Si
Por favor especifique las entidades (individuo, empresa, sociedad): beyond cosmeceuticals SA

¿Ha recibido algún pago, honorario u otra compensación por su trabajo acerca de esta investigación?
Si
Por favor especifique las entidades (individuo, empresa, sociedad): beyond cosmeceuticals SA

¿Tiene vínculos financieros con alguna entidad que podría llegar a competir estrechamente con los medicamentos, materiales o instrumentos tratados en su investigación?
Si
Por favor especifique las entidades (individuo, empresa, sociedad): beyond cosmeceuticals SA

¿Posee o ha solicitado una patente relacionada a los materiales, productos o instrumentos utilizados en su investigación?
No

Este trabajo es presentado gracias al apoyo de: beyond cosmeceuticals SA

Prof Philippe HUMBERT

Dermatólogo

Francia

Otro(s) autor(es) :

Benefits of oral supplementation for melasma

Prof Desmond J TOBIN

PhD - Investigación

Irlanda

Otro(s) autor(es) :

Modulation of skin pigmentation with topicals

Objectives: The literature is full of reports claiming to describe inhibitors (and more recently stimulators) of melanin synthesis and transfer. This talk will provide understanding of how modulation of skin pigmentation can be approached from several levels in terms of melanin synthesis (amount and subtype), transfer to keratinocytes, distribution within different epidermis strata and ultimate melanin fate. This talk with review our recent work in this area.

Introduction: Melanin is synthesized by melanocytes in the epidermis basal layer, and when transferred to keratinocytes is the key ultraviolet radiation-protective biopolymer responsible for skin pigmentation. However, most melanin is seen only in the proliferative basal layer and only sparsely above this. The latter has been explained (without convincing evidence) as 'melanin degradation' in suprabasal layers. We have recently re-evaluated how melanin is distribution in human epidermis under normal and stress conditions. Our new understanding allows us to reassess how melanin levels can be modulated.

Materials / method: Using skin tissues derived from normal healthy individuals of different skin phototype, and cell cultures derived from these tissues for standard bioscience experimental analysis.

Results: We have recently revisited the need to develop a new generation of safe topical ingredients, with cosmetic and therapeutic potential (vitiligo, Pityriasis alba etc.). We have identified a novel way to modulate the epidermal-melanin unit function, by mimicking a growth factor that stimulates melanogenesis and melanin transfer. Specifically, we have identified small peptide mimics of BMP6, by interrogating the binding site of BMP6 with its receptor. After cytotoxicity assessment in vitro, we have evaluated these in aqueous-soluble and topical form using pigmented human skin equivalents.

Conclusion: Some of these peptides exhibited the ability to increase melanogenesis when topically applied in a 3-D human skin model, and we believe that this technology offers significant benefits over the currently available technology. We are currently investigating whether these molecules may be modified to have the reverse activity on this melanogenesis pathway.

Declaraciones

¿Ha recibido algún tipo de financiamiento para realizar su investigación sobre esta temática?
No

¿Ha recibido algún pago, honorario u otra compensación por su trabajo acerca de esta investigación?
No

¿Tiene vínculos financieros con alguna entidad que podría llegar a competir estrechamente con los medicamentos, materiales o instrumentos tratados en su investigación?
No

¿Posee o ha solicitado una patente relacionada a los materiales, productos o instrumentos utilizados en su investigación?
No

Este trabajo no cuenta con el apoyo de ningún financiamiento directo o indirecto. El autor asume plena responsabilidad sobre el mismo.

¿Tiene una pregunta?

Encuentre las respuestas rápidamente en nuestra sección de FAQ.

Congresos

IMCAS Americas
IMCAS Asia
IMCAS World Congress

Acerca de

Empresa
Política de Confidencialidad
Mención legal

Academy

Inicio
Cursos
Webinars
Explorar
Blog

Subvenciones

Subvención educativa

Ponerse en contacto

Contáctenos

Nombre de usuario/Email

Contraseña

Mantenerme conectado

Iniciar sesión

Olvidé mi contraseña ? Todavía no tiene una cuenta? Inscríbase ahora

Mantenerme conectado

academy.Do_not_have_an_account_yet Inscríbase ahora

IMCAS World Congress 2019 Programa

FOCO EN S085

Melasma: change the color of your skin (in collaboration with SMD)

Moderador

Las presentaciones

Sesiones recomendadas

IMCAS World Congress 2019
Programa